20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Telix Pharmaceuticals Limited (TLX) operates in the BIOTECHNOLOGY industry and is headquartered in North Melbourne, Australia with about 1,120 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, TLX reported $1.2B in revenue and ($11M) in net income.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Interactive charts & full statements → Open the TLX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2011-12-31 | 2000-12-31 | 1999-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.3B | $1.2B | $783M | $503M | $160M | $8M | $5M | $3M | $0M | $32M | $29M | $32M | $28M | $21M | $23M | — | — |
| Gross Profit | $684M | $640M | $510M | $314M | $95M | $5M | $3M | ($12M) | $0M | $0M | $8M | $7M | $6M | $5M | ($17M) | — | — |
| Gross Margin % | 52.1% | 53.1% | 65.1% | 62.6% | 59.3% | 66.5% | 61.2% | -340.8% | 100.0% | -0.0% | 27.4% | 23.1% | 20.2% | 22.1% | -73.0% | — | — |
| Operating Income (EBIT) | ($10M) | $27M | $82M | $16M | ($92M) | ($81M) | ($44M) | ($36M) | ($29M) | ($7M) | $0M | $0M | ($5M) | ($2M) | $0M | ($1M) | ($1M) |
| Operating Margin % | -0.8% | 2.2% | 10.5% | 3.1% | -57.4% | -1069.6% | -847.7% | -1033.6% | -15016.1% | -20.5% | -0.1% | -0.4% | -17.9% | -9.1% | -0.1% | — | — |
| Net Income | $48M | ($11M) | $50M | $5M | ($104M) | ($81M) | ($45M) | ($28M) | ($14M) | ($6M) | $0M | $0M | $5M | ($3M) | ($3M) | $0M | $0M |
| Net Margin % | 3.7% | -0.9% | 6.4% | 1.0% | -65.0% | -1059.9% | -861.1% | -799.6% | -7087.1% | -20.1% | -0.1% | -0.4% | 19.2% | -12.0% | -10.8% | — | — |
| EBITDA | $46M | $80M | $98M | $23M | ($93M) | ($70M) | ($45M) | ($24M) | ($28M) | ($7M) | $0M | $0M | ($1M) | $2M | $5M | ($1M) | ($1M) |
| Earnings Per Share (EPS) | $0.13 | $-0.03 | $0.14 | $0.02 | $-0.34 | $-0.29 | $-0.17 | $-0.12 | $-0.07 | $-0.05 | $-0.00 | $-0.00 | $3.96 | $-1.98 | $-0.16 | $-0.01 | $-0.01 |
| Shares Outstanding (M) | 357M | 338M | 345M | 324M | 311M | 282M | 257M | 233M | 202M | 128M | 128M | — | 1M | — | 15M | 39M | 39M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $691M | $620M | $593M | $594M | $189M | $282M | $221M | $136M |
| Gross Profit | $357M | $327M | $288M | $386M | $124M | $224M | $91M | $45M |
| Gross Margin % | 51.6% | 52.8% | 48.6% | 64.9% | 65.6% | 79.5% | 41.1% | 33.0% |
| Operating Income (EBIT) | ($20M) | $10M | $16M | $68M | $14M | ($16M) | $31M | ($10M) |
| Operating Margin % | -2.9% | 1.6% | 2.7% | 11.5% | 7.3% | -5.5% | 14.2% | -7.1% |
| Net Income | $56M | ($7M) | ($3M) | $38M | $12M | $20M | ($14M) | ($33M) |
| Net Margin % | 8.0% | -1.2% | -0.6% | 6.4% | 6.2% | 6.9% | -6.5% | -24.4% |
| EBITDA | $17M | $29M | $9M | $83M | $40M | $23M | ($9M) | ($25M) |
| Earnings Per Share (EPS) | $0.16 | $-0.02 | $-0.01 | $0.11 | $0.03 | $0.06 | $-0.05 | $-0.10 |
| Shares Outstanding (M) | 357M | 339M | 337M | 345M | 351M | 324M | 318M | 316M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($19M) | ($26M) | $43M | $24M | ($64M) | ($59M) | $2M | ($23M) | ($21M) | ($6M) | ($1M) | ($4M) | ($2M) | ($1M) | ($1M) |
| Capital Expenditures (CapEx) | $68M | $57M | $14M | $10M | $7M | $1M | $0M | $0M | $0M | $0M | $3M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($87M) | ($83M) | $29M | $14M | ($71M) | ($61M) | $2M | ($24M) | ($21M) | ($6M) | ($4M) | ($4M) | ($2M) | ($1M) | ($1M) |
| FCF Margin % | -6.6% | -6.9% | 3.7% | 2.8% | -44.4% | -798.7% | 32.8% | -681.1% | -10734.6% | -19.0% | -13.3% | -11.6% | -7.0% | -6.7% | -2.5% |
| Dividends Paid | — | — | — | — | — | — | — | — | — | $55M | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2025-12-31 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $33M | ($53M) | $27M | $4M | $35M | $11M | $13M | ($4M) |
| Capital Expenditures (CapEx) | $27M | $40M | $10M | $10M | $5M | $7M | $3M | $5M |
| Free Cash Flow (FCF) | $6M | ($93M) | $17M | ($6M) | $30M | $4M | $10M | ($8M) |
| FCF Margin % | 0.9% | -14.9% | 2.8% | -1.0% | 16.1% | 1.4% | 4.6% | -6.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2011-12-31 | 2000-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.0B | $1.8B | $1.5B | $398M | $255M | $110M | $158M | $103M | $77M | $51M | $19M | $18M | $18M | $19M | $12M | $9M |
| Cash & Cash Equivalents | $364M | $213M | $710M | $123M | $116M | $22M | $78M | $45M | $26M | $49M | $1M | $1M | $1M | $0M | $1M | $3M |
| Total Liabilities | $1.3B | $1.1B | $948M | $249M | $175M | $106M | $79M | $33M | $24M | $2M | $20M | $18M | $20M | $17M | $23M | $0M |
| Total Debt (Short + Long-Term) | $527M | $420M | $573M | $10M | $5M | $1M | $1M | $0M | $1M | $0M | $4M | $1M | $2M | $2M | $1M | $0M |
| Total Shareholders' Equity | $704M | $622M | $568M | $149M | $80M | $2M | $79M | $70M | $53M | $49M | ($2M) | $0M | ($2M) | $2M | ($11M) | $9M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TLX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms